Vivimed Labs Quarterly Results for Trading Insights
In Sept 2025, Vivimed Labs (VIVIMEDLAB) reported revenue ₹21 Cr and net profit ₹-7 Cr — revenue -16.0% YoY. For annual financials, live price and key ratios, visit VIVIMEDLAB screener.
VIVIMEDLAB Quarterly Results — Revenue, Profit & EPS Highlights
Vivimed Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with VIVIMEDLAB fair price to assess whether the stock is under or overvalued.
- Revenue of ₹21 Cr in Sept 2025 (-30.0% vs Mar 2025, -16.0% vs Sept 2024)
- Net Profit of ₹-7 Cr in Sept 2025 (-16.7% vs Mar 2025, -40.0% vs Sept 2024)
- EBITDA of ₹-1 Cr in Sept 2025 (-150.0% vs Mar 2025)
- Operating Margin of -5.0% in Sept 2025 (+5.0pp vs Mar 2025)
- Earnings Per Share of ₹-0.88 in Sept 2025 (-29.4% vs Mar 2025)
Vivimed Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVIMEDLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 21 | 30 | 22 | 16 | 25 | -30.0% | -16.0% |
| Net Profit (₹ Cr) | -7 | -6 | -6 | -17 | -5 | - | - |
| EBITDA (₹ Cr) | -1 | 2 | 0 | -11 | -1 | - | - |
| EPS (₹) | -0.88 | -0.68 | -0.66 | -2.00 | -0.62 | - | - |
| Operating Margin (%) | -5.0% | -10.0% | -1.0% | -68.0% | -3.0% | - | - |
VIVIMEDLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Vivimed Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Vivimed Labs share price performance to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVIMEDLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivimed Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores